https://yakulens.jp/2026/09/08/irinotecan-ugt1a1-toxicity-risk/2026-09-07T16:57:42+00:00monthlyhttps://yakulens.jp/2026/09/08/gcsf-primary-prophylaxis-fn-risk/2026-09-07T16:42:01+00:00monthlyhttps://yakulens.jp/2026/09/08/vancomycin-piptazo-aki-risk/2026-09-07T16:41:32+00:00monthlyhttps://yakulens.jp/2026/09/08/ici-myocarditis-myositis-myasthenia-overlap/2026-09-07T16:20:05+00:00monthlyhttps://yakulens.jp/2026/09/08/vancomycin-auc-monitoring-not-trough-only-2/2026-09-07T16:19:33+00:00monthlyhttps://yakulens.jp/2026/09/08/tdxd-grade1-ild-rechallenge/2026-09-07T16:19:08+00:00monthlyhttps://yakulens.jp/2026/09/08/anti-egfr-hypomagnesemia-potassium-calcium/2026-09-07T16:18:44+00:00monthlyhttps://yakulens.jp/2026/09/08/olanzapine-5mg-ac-cinv-home-dosing/2026-09-07T16:18:27+00:00monthlyhttps://yakulens.jp/2026/09/08/apixaban-strong-cyp3a4-pgp-inhibitors/2026-09-07T16:17:57+00:00monthlyhttps://yakulens.jp/2026/09/08/low-dose-methotrexate-tmpsmx-toxicity/2026-09-07T16:17:40+00:00monthlyhttps://yakulens.jp/2026/09/08/cefepime-neurotoxicity-renal-function/2026-09-07T16:17:14+00:00monthlyhttps://yakulens.jp/2026/09/08/camizestrant-esr1-switch-before-progression/2026-09-07T16:16:51+00:00monthlyhttps://yakulens.jp/home-jp/2026-09-06T15:11:29+00:00weekly0.6https://yakulens.jp/oversight/2026-09-06T15:11:29+00:00weekly0.6https://yakulens.jp/30sec-check/2026-09-06T15:11:29+00:00weekly0.6https://yakulens.jp/deep-dive/2026-09-06T15:11:29+00:00weekly0.6https://yakulens.jp/comparison/2026-09-06T15:11:29+00:00weekly0.6https://yakulens.jp/hospital-pharm/2026-09-06T15:11:29+00:00weekly0.6https://yakulens.jp/new-drugs/2026-09-06T15:11:29+00:00weekly0.6https://yakulens.jp/oncology/2026-09-06T15:11:28+00:00weekly0.6https://yakulens.jpdaily1.02026-09-07T16:57:42+00:00